Overall survival benefit achieved with amivantamab plus lazertinib in advanced EGFR-mutated NSCLC
Final results from the MARIPOSA trial provide further supporting evidence to the first-line treatment combination
Novel ways presented to mitigate combination therapy toxicity in EGFR-mutant advanced NSCLC
Results from the ETOP AMAZE-lung and COCOON trials show some promise to improve safety and reduce skin adverse events
Subcutaneous pembrolizumab demonstrates noninferiority to intravenous administration
Phase III data in metastatic NSCLC support an alternative route of administering immunotherapy, which may have an impact on patients’ preferences and cancer care costs
Targeting KRAS G12C in NSCLC: balancing the benefit–risk profile of first-line combinations is still challenging
Studies evaluate the efficacy and safety of promising agents including adagrasib and fulzerasib
Promising activity reported with second-line TKIs in oncogene-addicted advanced NSCLC
Results from two trials could expand current options for patients with EGFR or HER2-activating mutations progressing on tyrosine kinase inhibitors
Telemedicine reduces delays in bone sarcoma management in rural India
A model implemented by a non-profit organisation exemplifies how virtual consultation and follow-up of patients with rare cancer can facilitate continuity of care
Two novel approaches provide new insights into prognostic markers for rare adrenal cancers
Detecting ctDNA and a simple four-component scoring system showed some predictive value, but require prospective validation
Real-world data has become integral to sarcoma research
Researchers’ confidence is growing, but the quality of the data generated may still represent a challenge
Long-term nirogacestat shows sustained benefits in desmoid tumours
Newly presented phase III trial and real-world findings reassure on the use of the gamma secretase inhibitor
Machine learning models predict adverse events and survival in patients receiving immunotherapy
New data supports the use of artificial intelligence for the administration of immune-check inhibitors in solid tumours